Seock‐Ah Im
A5069050806- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- PARP inhibition in cancer therapy
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- Cancer-related Molecular Pathways
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Breast Lesions and Carcinomas
- DNA Repair Mechanisms
- BRCA gene mutations in cancer
- Pancreatic and Hepatic Oncology Research
- Estrogen and related hormone effects
- Gastrointestinal Tumor Research and Treatment
- Ovarian cancer diagnosis and treatment
- PI3K/AKT/mTOR signaling in cancer
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- Chronic Lymphocytic Leukemia Research
Seoul National University Hospital
2016-2025
Seoul National University
2016-2025
National University College
2013-2024
New Generation University College
2015-2024
Asan Medical Center
2007-2024
Cancer Research Institute
2011-2024
Ulsan College
2017-2024
Fudan University Shanghai Cancer Center
2024
Harbin Medical University
2024
Third Affiliated Hospital of Harbin Medical University
2024
Unresectable locally advanced or metastatic triple-negative (hormone-receptor–negative and human epidermal growth factor receptor 2 [HER2]–negative) breast cancer is an aggressive disease with poor outcomes. Nanoparticle albumin-bound (nab)–paclitaxel may enhance the anticancer activity of atezolizumab.
Olaparib is an oral poly(adenosine diphosphate–ribose) polymerase inhibitor that has promising antitumor activity in patients with metastatic breast cancer and a germline BRCA mutation.
A phase 2 study showed that progression-free survival was longer with palbociclib plus letrozole than alone in the initial treatment of postmenopausal women estrogen-receptor (ER)–positive, human epidermal growth factor receptor (HER2)–negative advanced breast cancer. We performed a 3 designed to confirm and expand efficacy safety data for this indication.
The anti–human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab improves the outcome in patients with HER2-positive metastatic breast cancer. However, most cases of advanced disease eventually progress. Pertuzumab, an anti-HER2 that inhibits dimerization, has a mechanism action is complementary to trastuzumab, and combination therapy two antibodies shown promising activity acceptable safety profile phase studies involving
Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable. Currently available HER2-directed therapies have been ineffective in patients with these "HER2-low" cancers.
Patients who have residual invasive carcinoma after the receipt of neoadjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer poor prognoses. The benefit adjuvant in these patients remains unclear.We randomly assigned 910 with HER2-negative (containing anthracycline, taxane, or both) to receive standard postsurgical treatment either capecitabine without (control). primary end point was disease-free survival. Secondary points included overall...
Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and cytotoxic topoisomerase I inhibitor. In phase 1 dose-finding study, majority the patients with advanced HER2-positive breast cancer had response to trastuzumab (median duration, 20.7 months). The efficacy in metastatic previously treated emtansine requires confirmation.In this two-part, open-label, single-group,...
The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression-free survival among patients hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We report the results of a prespecified analysis overall survival. randomly assigned HER2-negative cancer who had progression or relapse during previous endocrine therapy to receive palbociclib plus placebo fulvestrant. analyzed...
Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer who were treatment naïve or had received up to one line of prior endocrine therapy the setting. Patients and Methods randomly assigned at a two-to-one ratio placebo fulvestrant. The primary end point was locally assessed progression-free survival. Secondary points included overall survival, response rate,...
An earlier analysis of this phase 3 trial showed that the addition a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided greater benefit with regard progression-free survival than alone in premenopausal or perimenopausal patients advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Here we report results protocol-specified interim key secondary end point overall survival.We randomly assigned receive either...
Trastuzumab emtansine is the current standard treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer whose disease progresses after a combination of anti-HER2 antibodies and taxane.We conducted phase 3, multicenter, open-label, randomized trial to compare efficacy safety trastuzumab deruxtecan (a HER2 antibody-drug conjugate) those in HER2-positive previously treated taxane. The primary end point was progression-free survival (as...
This study was undertaken to investigate the effects of epidermal growth factor receptor (EGFR) mutation and its downstream signaling on response survival in non-small-cell lung cancer (NSCLC) patients treated with gefitinib.For 90 consecutive NSCLC who had received gefitinib, EGFR analyzed by DNA sequencing exons 18, 19, 21, 23 tyrosine kinase domain. Expressions phosphorylated (p) -Akt p-Erk were determined via immunohistochemistry. Response rate, time progression (TTP), overall compared...
In an earlier analysis of this phase 3 trial, ribociclib plus fulvestrant showed a greater benefit with regard to progression-free survival than alone in postmenopausal patients hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer. Here we report the results protocol-specified second interim overall survival.
In the OlympiAD study, olaparib was shown to improve progression-free survival compared with chemotherapy treatment of physician's choice (TPC) in patients a germline BRCA1 and/or BRCA2 mutation (BRCAm) and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC). We now report planned final overall (OS) results, describe most common adverse events (AEs) better understand tolerability this population.
In an interim analysis of this phase 3 trial, the addition pembrolizumab to chemotherapy resulted in longer progression-free survival than alone among patients with advanced triple-negative breast cancer whose tumors expressed programmed death ligand 1 (PD-L1) a combined positive score (CPS; number PD-L1–staining tumor cells, lymphocytes, and macrophages, divided by total viable multiplied 100) 10 or more. The results final overall have not been reported.
Abstract At the MONARCH 3 interim analysis, abemaciclib plus a nonsteroidal aromatase inhibitor (AI) significantly improved progression-free survival (PFS) and objective response rate (ORR) with tolerable safety profile as initial treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC). is randomized, phase III, double-blind study of abemaciclib/placebo (150 mg twice daily, continuous) AI (1 anastrozole or 2.5...